跳至主要内容
临床试验/NCT03361202
NCT03361202Unknown不适用

Evolution of Microparticles Circulating Plasma Concentration in Atrial Fibrillation After Percutaneous Occluding of the Left Atrium With Prosthesis (Amplatzer® Cardiac Plug)

Institut Mutualiste Montsouris1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2015年1月最近更新:
适应症

试验速览

阶段
不适用
入组人数
50
试验地点
1
主要终点
levels of microparticles expressing phosphatidylserine in atrial fibrillation group

研究概览

简要总结

The aim of the study is to compare levels of differnts types of microparticles circulating before and after percutaneous occluding of the left atrium by patients with atrial fibrillation and patients control.

Hypothesis is that prothesis implantation will decrease levels of microparticles circulating in blood circulation because of occluding of the left atrium .

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • atrial fibrillation group:
  • high embolic risk (CHADS-VASC2 score ≥4)
  • formal and final contraindication to anticoagulant therapy
  • no heart thrombus on ETO and TDM before percuraneous occluding
  • control group:
  • suspicion of stable coronary artery disease, coronary angiography scheduled and double platelet aggregation (clopidogrel and aspirine)

排除标准

  • for both groups
  • congestive heart failure, severe aortic stenosis, EP or TVP early.

结局指标

主要结局

levels of microparticles expressing phosphatidylserine in atrial fibrillation group

时间窗: 45 days after Percutaneous Occluding of the Left Atrium.

blood samples analized by flow cytometry

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Microparticles Circulating Plasma Concentration in... | 临床试验